Lantheus Holdings, Inc. Business Acquisition, Pro Forma Net Income (Loss)
Lantheus Holdings, Inc. (LNTH) reported Business Acquisition, Pro Forma Net Income (Loss) of -$29.19 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2023-02-23
- Lantheus Holdings, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2020-12-31 was -$56.33M.
- Lantheus Holdings, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2020-09-30 was $45.26M, a 995.57% increase year-over-year.
- Lantheus Holdings, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2019-12-31 was -$89.06M.
- Lantheus Holdings, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2019-09-30 was $4.13M.
- Lantheus Holdings, Inc. business acquisition, pro forma net income (loss) for fiscal 2020 was -$29.19M.
- Lantheus Holdings, Inc. business acquisition, pro forma net income (loss) for fiscal 2019 was -$42.03M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|---|
| 2020-12-31 | -$56.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$11.07M derived: sum of 2 quarters · filed 2023-02-23 | -$29.19M 10-K · filed 2023-02-23 | ||
| 2020-09-30 | $45.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $27.14M 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | -$18.11M 10-Q · filed 2021-07-28 | $18.11M 10-Q · filed 2020-07-31 | |||
| 2019-12-31 | -$89.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$84.93M derived: sum of 2 quarters · filed 2022-02-24 | -$42.03M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $4.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $47.03M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $42.90M 10-Q · filed 2020-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |